InSphero expands its high-content imaging capabilities with acquisition of PhenoVista Biosciences
- 7 days ago
- 2 min read
Updated: 3 days ago
20 May 2026
Zurich-based CRO InSphero, global leader in advanced 3D in vitro products and services, announces the acquisition of PhenoVista Biosciences to expand its high-content imaging and phenotypic analysis capabilities for drug discovery and safety testing.
San Diego-based CRO PhenoVista Biosciences, Inc., is a leading provider in high-content imaging, cell painting, and functional cellular analysis for the biopharmaceutical industry. Their diverse repertoire includes working with primary cells, iPSC-derived neurons and glia, and client-engineered lines in a variety of formats.
The acquisition marks another major milestone in InSphero’s growth journey and reinforces the company’s position as a leading global platform for microphysiological systems. Building on the recent acquisition of DOPPL SA, designer of high-content assays that integrate imaging, analytics, and functional readouts, the addition of PhenoVista broadens InSphero’s scientific capabilities and strengthens its operational presence in the United States, enabling more pharmaceutical and biotechnology scientists in this key market to access advanced, industry-ready in vitro technologies and services.
“Over the past 17 years, InSphero has built a strong reputation for scientific excellence, operational robustness, and innovation in predictive in vitro biology. With PhenoVista joining InSphero, we are adding highly complementary expertise, an exceptional team, and a stronger operational presence in the US market. Most importantly, this acquisition allows us to serve our customers even better by combining cutting-edge biology with advanced imaging and phenotypic analysis in an increasingly integrated way with fast turn-around times.” said Dr. Jan Lichtenberg, CEO and Co-founder, InSphero.
“PhenoVista and InSphero share a common vision for the future of drug discovery. Both organizations believe that better human-relevant models, advanced analytics, and scientific collaboration are essential to improving the speed and quality of biomedical innovation. Together, we are exceptionally well-positioned to help customers address increasingly complex biological questions.” said James G. Evans, CEO, PhenoVista Biosciences.
This latest acquisition reflects InSphero’s continued commitment to building a globally integrated organization capable of delivering best-in-class technologies, scientific services, and operational excellence to customers worldwide.
For weekly news, trends and insights on human‑based in vitro approaches, explore your access options.
